AUTL
$1.51
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company's clinical-stage programs include obecabtagene ...
Recent News
European Equities Traded in the US as American Depositary Receipts Edge Lower in Wednesday Trading
European equities traded in the US as American depositary receipts edged lower late Wednesday mornin
European Equities Traded in the US as American Depositary Receipts Decline in Monday Trading
European equities traded in the US as American depositary receipts were tracking slightly lower late
European Equities Traded in the US as American Depositary Receipts Fall in Friday Trading; Down 5% for Week
European equities traded in the US as American depositary receipts were down sharply late Friday mor
European Equities Traded in the US as American Depositary Receipts Slide in Thursday Trading
European equities traded in the US as American depositary receipts were sliding late Thursday mornin
Autolus Therapeutics Touts $75M Year-1 Obe-cel Launch, Sees $120M-$135M Revenue in 2026
Autolus Therapeutics (NASDAQ:AUTL) Chief Executive Officer Christian Itin told conference attendees the company is entering its second year as a commercial-stage business following the launch of its first product, obe-cel, a CD19 CAR-T therapy approved for adult patients with relapsed or refractory